There exists a major issue that affects almost all early-stage startups – the gap in funding and expertise between their seed and Series A rounds and beyond. With component shortages and enhanced regulatory requirement, European MedTech start-ups may face a longer time-to-market and increased need for cashflow. How is the current investment landscape for early-stage MedTech in Europe? Which alternative funding options to VCs exist for MedTech start-ups facing a funding gap and how prevalent are corporates today? How to avoid a chicken and egg problem if you cannot de-risk your asset without sufficient funding?
Moderator: Adriana Diaz, Communities Manager, ECHAlliance